CLOGGED LUNGS CLEARED:
STOPPING AMERICA’S 4TH BIGGEST KILLER

When one of our contacts called us about a product he referred to as “truly bizarre,” I thought “How ‘out there’ can it really be?” After all, we come across some pretty unique and complex stuff almost daily in the course of our research. But in this case, there really is no other word to describe the novel treatment for cystic fibrosis, chronic obstructive pulmonary disease, and other respiratory ailments that he told me about: Bizarre sums it up nicely.

It’s a liquid formula of DNA called Mucolyxir that, applied sublingually, helps dissolve airway blocking mucous. That’s right––DNA under your tongue to help you breathe better: See what we mean by bizarre? But not only does it appear to be safe and effective, it also costs much less than you might expect for something this revolutionary. Ancient theory meets modern science
One of the primary theories explaining respiratory diseases is that much of the mucous blocking the airways is a result of the immune system’s effort to eliminate bacteria from the lungs. Mucolyxir’s developers, John McMichael and Allan Lieberman, took that theory and further hypothesized that such activity, over time, could result in hypersensitivity that would exacerbate the problem of mucous accumulation. To address this problem, they turned to the ancient homeopathic concept of “like cures like.”
As you’ll see below, much of the mucous buildup involved in respiratory illnesses like cystic fibrosis and chronic obstructive pulmonary disease (COPD) is caused by accumulated DNA. So McMichael and Lieberman chose the “like” cure––DNA––as the basis for their Mucolyxir formula. DNA therapy interrupts vicious cycle Inside the lungs, the scenario might go something like this: Bacterial-DNA induces the production of various interleukins (such as IL-8), which are associated with inflammation. The presence of IL-8 sends out a distress signal through your body.

In turn, responding immune cells attack and destroy the invaders by engulfing them in mucous. But as the immune cells respond, they spill their own DNA, which is interpreted as an enemy invader in the respiratory environment. This sparks another signal for help, establishing a vicious and continually amplified cycle as the immune cells are repeatedly called into play.

Mucolyxir interrupts this cycle by reducing the production of “signaling” interleukins in order to decrease the production of the protective mucous, which is often more harmful than helpful. It does this in two ways: by regulating anti-DNA activity of the immune system, and by clearing mucous to eliminate matter clogging the airways.

Mucociliary clearance involves the movement of the cilia (the tiny arm-like fibers on the cells lining the bronchial tree), secretion of mucous, and movement of water into and out of epithelial cells. In plain English, that means that the tiny fibers in your lungs are stimulated, causing mucous secretion and movement of water, which, basically, forces you to “cough up” the material clogging your airway. The DNA in Mucolyxir stimulates this process. The DNA that McMichael and Lieberman used in creating Mucolyxir was extracted from salmon, but it’s important to understand that there is no gene transfer with this method of DNA use. In other words, you won’t suddenly start showing characteristics of salmon. I spoke to Dr. Lieberman to ask how we can be sure that there’s no risk of this happening: After all, you don’t need gills or fins. He explained that Mucolyxir uses a microdose of
DNA, meaning that there is not even one full genome present in the product. He pointed out that we eat foreign DNA all the time: When you eat a sardine, you are eating the complete sardine DNA, yet you don’t take on any characteristics of a sardine. Fortunately, it just doesn’t work that way.

Dr.McMichael noted that, based on his observations, Mucolyxir appears to be “helpful in the treatment of severe respiratory conditions like chronic bronchitis and COPD. People treated with it demonstrate significant improvements in objective parameters
such as improved pulmonary function leading to better blood oxygenation efficiency and exercise ability. This product has been formulated to address an unmet medical need that affects a large number of people worldwide.” And that “large number” is growing every day.

While cigarette smoke and work environments (such as textile manufacturing and mining) are the most common causes of COPD, it’s not just the smokers, miners, and manufacturers at risk. A new generation in respiratory trauma is on the rise, one brought on by irritants like toxic mold found inside-possibly even in your own home. These conditions can lead to cases of asthma and COPD.
While pinning down and eliminating these factors is obviously the best solution, that may not always be possible––especially before the onset of respiratory problems. But the good news is that although the formula was originally developed to treat cystic fibrosis (CF), research also supports Mucolyxir’s potential for stimulating an immune response that can protect against or reduce symptoms of asthma and COPD. Real-world results for conditions from CF to chronic sinusitis This all still sounds a little like science fiction, but the applications of Mucolyxir are certainly showing real-word results. While it doesn’t cure severe respiratory disease, it does make the symptoms more manageable, in turn, improving quality of life. And although there are no controlled clinical trials at this point, there are some remarkable anecdotal accounts.
Consider the case study of 23-year-old twin brothers, both afflicted with cystic fibrosis. Each had a history of hospitalizations for lung clearance and secondary infections diagnosed as being associated with their cystic fibrosis. Each brother began therapy with one or two drops (0.0006 mg/drop) of
DNA sublingually per day. For almost seven years since beginning DNA therapy, neither has been hospitalized. In addition,
follow-up evaluations by physicians revealed a 30 to 45 percent increase in airflow in each patient. And that’s not all: Forced vital capacity, a common measure of lung capacity, and the extent of mucous clearance in the lungs increased from 60 to 90 percent. After approximately one year of therapy, one of the brothers stopped taking the DNA drops. His condition steadily worsened, with increased mucous viscosity, decreased lung capacity, and reduced expectoration. When he resumed taking the DNA drops at the prescribed dose, he immediately improved once again.

Another example of Mucolyxir’s potential is that of a 48-year-old woman with chronic sinusitis and bronchitis characterized by chronic head congestion, nasal obstruction, and coughing. She also began treatment with one drop per day of DNA. After just a few days, she noted a dramatic improvement in sinus and chest drainage. Again, when she stopped taking the DNA drops, her condition regressed. Beginning therapy again caused a similar increase in drainage and relief of congestion she’d experienced previously. Our medical adviser, Dr. Martin Milner, also told us that people with acute or chronic asthma who have excessive mucus production could also be helped by Mucolyxir.
Recommended protocol - When I spoke with Dr. Lieberman, I also asked him to explain what exactly is involved in using Mucolyxir. He told me that it is administered sublingually (under the tongue) in doses of just one drop at a time. The single drop should be applied on the floor of the mouth, behind the lower teeth, and you should refrain from swallowing for 15 seconds. To avoid dilution, you should also avoid eating or drinking for five minutes after application.
He emphasized that all patients, regardless of diagnosis, are advised to employ the “rush technique” on the first day of using Mucolyxir. This technique involves taking one drop every 15 minutes for one hour. After the first hour, take one drop every hour until bedtime. On the second and third days of treatment, take one drop four times daily: one after each meal and one before bed.

Beginning on day four, use only as needed––more drops on days with severe symptoms, fewer on good days. Now, what about cost? A formula based on DNA certainly sounds like it would be expensive. But, at about $35, Mucolyxir is actually fairly affordable, especially considering the cost, in terms of potentially dangerous side effects, associated with the mainstream treatments––like bronchodilators, antibiotics, and even lung transplants––currently used for cystic fibrosis and COPD. The drops are stable whether they’re refrigerated or at room temperature, so you can carry them with you, for quick easy access, in your pocket, purse, or briefcase without worry in each patient.